Convicted rapist John Rolfe's sentencing is scheduled for 8:15 a.m. on June 21. Rolfe, 60, was convicted of three counts of first-degree rape and 12 counts of possession, manufacture and/or ...

Simon Nemec would get the game winner in double overtime for a 3-2 win over the Hurricanes in Game 3 to draw the Devils within two games to one in the series. With a goal 2:46 into the second ...

Simon Property Group, Inc. PFD J 8.375% SEC Filing - Annual Report (10-K) February 21, 2025 SEC Filings Fri, Feb. 21 Simon Property Group, Inc. PFD J 8.375% declares $1.0469 dividend ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...

Palm Beach Modern Auctions’ season-opener sale next weekend promises design enthusiasts and art collectors a feast for the senses. The auction preview is currently open to the public in their ...

Simon Benoit scored at 1:19 of overtime to give the Maple Leafs a commanding 3-0 lead in their best-of-seven series against the Senators. Benoit, who assisted on Max Domi's Game 2 overtime goal ...

Simon Schuessler joined the WSFA 12 News team in January of 2024. Growing up, while his friends were busy watching Netflix shows and cartoons, Simon was busy watching documentaries and NBC Nightly ...

NEWARK, N.J. − The New Jersey Devils have never been ... held and built a two-goal lead that would eventually evaporate. Simon Nemec would get the game winner in double overtime against the ...

It also said that J&J has reached an agreement with one of the lawyers resisting a deal, Allen Smith, who along with another firm represents around 12,000 plaintiffs out of several tens of ...

A dealership's rating is based on all of their reviews, with more weight given to recent reviews. Want to share your experience with this dealership? Scammers. They look for desperate clout ...

Once-daily oral IL-23 inhibitor icotrokinra (formerly JNJ-2113) – which J&J licensed from Protagonist Therapeutics in 2017 – hit both its main efficacy objectives in the ICONIC-LEAD trial ...